

Branislav Strauch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/65889/publications.pdf>

Version: 2024-02-01

44
papers

2,241
citations

257357

24
h-index

302012

39
g-index

45
all docs

45
docs citations

45
times ranked

2502
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence and blood pressure control in patients with primary aldosteronism. <i>Blood Pressure</i> , 2022, 31, 58-63.	0.7	1
2	Primary Aldosteronism and Pregnancy. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 275-285.	0.9	16
3	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5170-5180.	1.8	28
4	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. <i>Cancers</i> , 2019, 11, 318.	1.7	13
5	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. <i>Cancers</i> , 2019, 11, 485.	1.7	2
6	(Prediction of long-term renal denervation efficacy). <i>Cor Et Vasa</i> , 2019, 61, e378-e384.	0.1	0
7	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2422.	1.8	14
8	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. <i>Journal of Hypertension</i> , 2017, 35, 1093-1099.	0.3	25
9	Risk Factors for Nonadherence to Antihypertensive Treatment. <i>Hypertension</i> , 2017, 69, 1113-1120.	1.3	150
10	Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. <i>Hypertension</i> , 2017, 70, 1042-1048.	1.3	132
11	Should All Patients with Resistant Hypertension Receive Spironolactone?. <i>Current Hypertension Reports</i> , 2016, 18, 81.	1.5	6
12	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. <i>Journal of Human Hypertension</i> , 2016, 30, 35-39.	1.0	19
13	Laparoscopic adrenalectomy: institutional Czech experience after almost 300 operations. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2016, 48, 121-124.	0.3	0
14	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. <i>Hypertension</i> , 2016, 67, 397-403.	1.3	73
15	Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. <i>Journal of Hypertension</i> , 2015, 33, 874-882.	0.3	35
16	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 1109-1117.	1.0	29
17	Biochemical Testing After Pheochromocytoma Removal: How Early?. <i>Hormone and Metabolic Research</i> , 2015, 47, 633-636.	0.7	1
18	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. <i>Hypertension</i> , 2015, 65, 407-413.	1.3	178

#	ARTICLE	IF	CITATIONS
19	Eligibility for Renal Denervation. <i>Hypertension</i> , 2014, 63, 1319-1325.	1.3	61
20	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. <i>Journal of Human Hypertension</i> , 2014, 28, 684-688.	1.0	23
21	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. <i>European Heart Journal</i> , 2014, 35, 3122-3133.	1.0	249
22	Changes in Energy Metabolism in Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1651-1658.	1.8	49
23	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. <i>Journal of Hypertension</i> , 2013, 31, 2455-2461.	0.3	136
24	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 529-533.	0.9	30
25	High Incidence of Cardiovascular Complications in Pheochromocytoma. <i>Hormone and Metabolic Research</i> , 2012, 44, 379-384.	0.7	138
26	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 426-434.	1.0	8
27	Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 205-210.	0.9	14
28	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. <i>Hypertension Research</i> , 2011, 34, 296-300.	1.5	42
29	How to assess non-compliance with the pharmacotherapy in severe resistant hypertension?. <i>Cor Et Vasa</i> , 2011, 53, 429-432.	0.1	1
30	Development of a fast LC-MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. <i>Journal of Mass Spectrometry</i> , 2010, 45, 1179-1185.	0.7	7
31	Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: Application to document non-compliance of patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3167-3173.	1.2	26
32	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. <i>Journal of Human Hypertension</i> , 2010, 24, 625-630.	1.0	57
33	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. <i>Hypertension Research</i> , 2010, 33, 454-459.	1.5	34
34	Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. <i>Journal of Human Hypertension</i> , 2009, 23, 350-358.	1.0	15
35	INCREASED CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH PHEOCHROMOCYTOMA IN COMPARISON TO ESSENTIAL HYPERTENSION. <i>Atherosclerosis Supplements</i> , 2008, 9, 158.	1.2	0
36	Adrenalectomy Improves Arterial Stiffness in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2008, 21, 1086-1092.	1.0	89

#	ARTICLE	IF	CITATIONS
37	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. <i>NeuroImmunoModulation</i> , 2007, 14, 57-64.	0.9	38
38	Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1451-1457.	0.3	85
39	We-P11:195 Comparison of carotid intima-media thickness in patients with primary and secondary hypertension. <i>Atherosclerosis Supplements</i> , 2006, 7, 389.	1.2	0
40	Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration. <i>Blood Pressure</i> , 2006, 15, 302-307.	0.7	14
41	Increased Arterial Wall Stiffness in Primary Aldosteronism in Comparison With Essential Hypertension. <i>American Journal of Hypertension</i> , 2006, 19, 909-914.	1.0	96
42	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. <i>Journal of Hypertension</i> , 2005, 23, 2033-2039.	0.3	45
43	Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. <i>Journal of Human Hypertension</i> , 2004, 18, 107-111.	1.0	49
44	Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. <i>Journal of Human Hypertension</i> , 2003, 17, 349-352.	1.0	213